Work

Cost-effectiveness analysis of the prevention of relapse of schizophrenia in the longitudinal study Ziprasidone Extended Use in Schizophrenia (ZEUS).

Year: 2007
Type: article
Abstract: OBJECTIVE: Estimate the cost-effectiveness of the prevention of relapse of schizophrenia in the ZEUS (Ziprasidone Extended Use in Schizophrenia Study) longitudinal study that compares ziprasidone with the option of not treating. METHODS: One year of treatment was analyzed using the randomized clinical trial data (ZEUS study) with a deterministic model, having cost-effectiveness analysis type, conducted from the perspective of the National Health Care System (NHCS). RESULTS: Additional mean yearly cost for worsening avoided with ziprasidone was 186 Pounds for the mean dose, ranging from -556 Pounds (savings) with the 80 mg/day dose and 1,014 Pounds with 160 mg/day, which was always lower than the minimum cost of a relapse (2,830 Pounds), considered as threshold value to establish cost-effectiveness of treatment with ziprasidone. CONCLUSIONS: Prevention of relapse of schizophrenia with long-term ziprasidone is cost-effective in comparison with the option of not treating. Treatment with ziprasidone avoids relapse episodes at a reasonable cost, generating savings for the NHCS.
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W2409757414
FWCI: 0.507
Cites: 11
Cited by: 10
Related to: 9